Observational studyJournal of neurology2026
Clinical outcomes at 6 months after MRgFUS thalamotomy in Parkinson's disease: a large longitudinal cohort study.
Observational study in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMagnetic resonance-guided focused ultrasound (MRgFUS) is an expanding therapy for tremor in Parkinson's disease (PD). This study aimed to characterize trajectories of tremor and cognitive functions following MRgFUS treatment over 24 hours, 1 month, and 6 months, and to explore potential predictors of outcomes.
methodsThis single-center, prospective, observational cohort study included PD patients undergoing MRgFUS over a 7-year period. Tremor severity was assessed using the Fahn-Tolosa-Marin Tremor Rating Scale (FTM) and the Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III). Cognitive performance was evaluated using the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA).
results107 patients were included. Tremor severity showed a significant time effect (FTM and MDS-UPDRS-III: both p < 0.001), with a marked reduction at 24 hours followed by partial attenuation and stabilization over time, while remaining lower than baseline at 1 and 6 months (both p < 0.001). The 24-hour improvement was greater in patients with longer disease duration, who showed higher baseline severity (p < 0.001) and converged to cohort-level severity at post-treatment timepoints (all p ≥ 0.085). Cognitive status (MMSE and MoCA scores) remained stable throughout follow-up (all p ≥ 0.287). Levodopa equivalent daily dose (LEDD) significantly decreased from baseline to 6 months (F = 19.992, p < 0.001), suggesting a reduced need for dopaminergic treatment following tremor improvement.
conclusionsMRgFUS provided meaningful tremor improvement without negative effects on cognition. The significant LEDD reduction at 6 months supports a beneficial medication-sparing effect associated with tremor improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.